GO
Loading...

Eli Lilly and Co

More

  • Midday Glance: Pharmaceuticals companies Friday, 11 Jul 2014 | 1:37 PM ET

    Baxter International Inc. fell$. 54 or. 7 percent, to $76.21. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.44. Hospira fell$. 34 or. 7 percent, to $50.72.

  • Early Glance: Pharmaceuticals companies Friday, 11 Jul 2014 | 10:30 AM ET

    Baxter International Inc. fell$. 54 or. 7 percent, to $76.21. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $48.40. Hospira fell$. 22 or. 4 percent, to $50.84.

  • Midday Glance: Pharmaceuticals companies Thursday, 10 Jul 2014 | 1:44 PM ET

    Baxter International Inc. rose$. 65 or. 9 percent, to $76.47. Bristol-Myers Squibb Co. rose$. 58 or 1.2 percent, to $48.50. Hospira fell$. 56 or 1.1 percent, to $50.95.

  • Early Glance: Pharmaceuticals companies Thursday, 10 Jul 2014 | 11:01 AM ET

    Baxter International Inc. fell$. 10 or. 1 percent, to $75.72. Bristol-Myers Squibb Co. fell$. 09 or. 2 percent, to $47.83. Hospira fell$. 71 or 1.4 percent, to $50.80.

  • Midday Glance: Pharmaceuticals companies Tuesday, 8 Jul 2014 | 1:41 PM ET

    Baxter International Inc. rose$. 14 or. 2 percent, to $75.02. Bristol-Myers Squibb Co. fell$. 44 or. 9 percent, to $47.57. Hospira fell$. 54 or 1.0 percent, to $51.20.

  • Early Glance: Pharmaceuticals companies Tuesday, 8 Jul 2014 | 10:30 AM ET

    Baxter International Inc. fell$. 04 or. 1 percent, to $74.84. Bristol-Myers Squibb Co. fell$. 62 or 1.3 percent, to $47.39. Hospira fell$. 55 or 1.1 percent, to $51.19.

  • Final Glance: Pharmaceuticals companies Thursday, 3 Jul 2014 | 5:15 PM ET

    Baxter International Inc. fell$. 11 or. 1 percent, to $74.88. Bristol-Myers Squibb Co. rose$. 20 or. 4 percent, to $48.44. Hospira fell$. 15 or. 3 percent, to $52.49.

  • Midday Glance: Pharmaceuticals companies Thursday, 3 Jul 2014 | 1:17 PM ET

    Baxter International Inc. fell$. 11 or. 1 percent, to $74.88. Bristol-Myers Squibb Co. rose$. 17 or. 4 percent, to $48.41. Hospira fell$. 15 or. 3 percent, to $52.49.

  • Early Glance: Pharmaceuticals companies Thursday, 3 Jul 2014 | 10:30 AM ET

    Baxter International Inc. fell$. 32 or. 4 percent, to $74.67. Bristol-Myers Squibb Co. rose$. 11 or. 2 percent, to $48.35. Hospira fell$. 17 or. 3 percent, to $52.47.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than injectable insulins such as Eli Lilly and Co's Humalog and Novo Nordisk's NovoLog.

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk.

  • A three-judge panel of the 6th U.S. Circuit Court of Appeals in Cincinnati rejected claims in 67 of the cases. Among the defendants in the various cases were Eli Lilly& Co, which won regulatory approval for Darvon in 1957 and Darvocet in 1972, and generic drug makers such as Mylan Inc and Teva Pharmaceutical Industries Ltd..

  • *Sanofi hit may be limited as EU market smaller than U.S. LONDON, June 27- European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015..

  • *Novo Nordisk deputy CEO sees group growing 10 pct annually. COPENHAGEN, June 25- Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • Midday movers: General Electric, Eli Lilly & More Wednesday, 11 Jun 2014 | 1:02 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Wednesday's midday movers:

  • UPDATE 1-Lilly's Cyramza fails in liver cancer trial Wednesday, 11 Jun 2014 | 10:13 AM ET

    June 11- Eli Lilly and Co's recently approved stomach cancer drug Cyramza failed to prolong the lives of patients with advanced liver cancer in a late-stage trial, the drugmaker said on Wednesday.

  • CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.

  • BRUSSELS/ OTTAWA, June 2- Canada and the European Union are struggling to finalize a multibillion-dollar trade pact six months after political leaders said it was sealed, an embarrassment for Brussels as it seeks a far bigger deal with the United States.

  • ZURICH, June 2- Roche is betting the same tools that made it the world's largest producer of cancer drugs will help it tackle the growing public health crisis of antibiotic resistance as regulators and politicians encourage fresh research.